HC Wainwright Issues Optimistic Estimate for DAWN Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Day One Biopharmaceuticals from ($0.30) to ($0.27) per share and maintains a "Buy" rating with a target price of $25.00.
• Day One Biopharmaceuticals reported a Q2 loss of ($0.29) per share, beating analyst expectations of ($0.35), and had revenues of $33.91 million, falling short of the $35.55 million consensus estimate.
• Insider selling has occurred recently, with General Counsel and CFO both reducing their holdings, amid reports that institutional investors, like FMR LLC, have increased their stakes in the company.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Wednesday, August 6th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.27) per share for the quarter, up from their prior forecast of ($0.30). HC Wainwright currently has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals' FY2025 earnings at ($1.20) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at $0.33 EPS, FY2028 earnings at $0.51 EPS and FY2029 earnings at $1.01 EPS.

Several other analysts have also recently commented on DAWN. Wedbush reiterated an "outperform" rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. Needham & Company LLC dropped their price target on Day One Biopharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $25.33.

Day One Biopharmaceuticals Stock Performance

Shares of Day One Biopharmaceuticals stock traded up $0.19 on Friday, hitting $6.09. 2,050,864 shares of the company traded hands, compared to its average volume of 1,374,569. Day One Biopharmaceuticals has a 52 week low of $5.64 and a 52 week high of $16.76. The business has a 50-day simple moving average of $6.67 and a 200 day simple moving average of $7.94. The stock has a market capitalization of $623.29 million, a P/E ratio of -6.42 and a beta of -1.26.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $33.91 million during the quarter, compared to analyst estimates of $35.55 million. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative return on equity of 19.01%.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $27,000. Entropy Technologies LP bought a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth $67,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth $76,000. Quantbot Technologies LP bought a new position in shares of Day One Biopharmaceuticals during the 1st quarter worth $82,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of Day One Biopharmaceuticals during the 1st quarter worth $87,000. Institutional investors own 87.95% of the company's stock.

Insider Transactions at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 4,552 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $28,495.52. Following the sale, the general counsel owned 47,136 shares in the company, valued at approximately $295,071.36. This represents a 8.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeremy Bender sold 13,964 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total value of $87,414.64. Following the sale, the chief executive officer owned 145,737 shares in the company, valued at $912,313.62. The trade was a 8.74% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,725 shares of company stock valued at $167,299 in the last ninety days. Corporate insiders own 6.20% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.